Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating mavorixafor, a drug being studied for people aged 12 and older who have congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders. These conditions cause low neutrophil levels and lead to recurrent or serious infections. The study aims to show if mavorixafor can improve clinical outcomes and increase neutrophil counts, while also assessing its safety and tolerability. Participants will continue their current treatment during the study, which may include therapies like granulocyte-colony stimulating factor G-CSF, immunoglobulin replacement, antibiotics, or no active treatment. They will be randomly assigned to receive either mavorixafor or a placebo orally once daily for up to 52 weeks. The study uses a quadruple-blind design to compare these groups in parallel. During the trial, participants will have regular assessments to monitor infection rates and severity, neutrophil counts, antibiotic use, oral ulcers, and fatigue levels using questionnaires. An independent committee will review infections to ensure accuracy. Safety and treatment effects will be followed throughout the 52-week treatment period. The total participation may last until the study ends in late 2027.
Actively Recruiting
Researchers are evaluating the effectiveness of different volumes of serratus posterior superior intercostal plane SPSIP block for managing pain after unilateral breast surgery with axillary lymph node dissection. This study will compare three groups receiving 20 mL, 30 mL, or 40 mL of 0.25% bupivacaine to understand which volume best controls postoperative pain. The trial is randomized and double-blind to ensure reliable comparison among the groups. Participants will receive a single ultrasound-guided SPSIP block before general anesthesia. The local anesthetic will be injected between the serratus posterior superior and intercostal muscles at the T3-T4 level using one of the three volumes of 0.25% bupivacaine. Ninety participants will be assigned to one of these three dosing groups to assess differences in pain control. During the study, researchers will monitor tramadol use in the first 24 hours after surgery as the main outcome. They will also evaluate pain intensity at multiple time points, the time to first pain medication request, use of rescue analgesics, recovery quality, nausea and vomiting, block success, and any complications related to the block. The study is expected to last from March 2026 to February 2027, with participants closely monitored during the immediate postoperative period.
Actively Recruiting
Researchers are studying chronic myeloid leukemia CML, a rare blood cancer, in children and adolescents under 18 years old. This international observational study aims to better understand the characteristics, treatment approaches, and prognostic factors of pediatric CML. It also seeks to evaluate the long-term effects of treatments, especially tyrosine kinase inhibitors, on growth and development in this young population. The study collects both retrospective and prospective data from medical records and databases, without administering new treatments or interventions. Data gathered include demographic details, diagnosis information, treatment histories, and follow-up outcomes. National coordinating centers in participating countries gather anonymized patient data and send it to a central data center in France for analysis. Participants data are collected and updated twice yearly, with ongoing monitoring to describe patient characteristics and treatment policies. Researchers analyze survival, response to treatment, side effects, and long-term outcomes. The study is expected to continue for about five years, with results shared regularly with participating centers and published anonymously.
Actively Recruiting
Researchers are conducting an observational study to screen adults aged 18 and over who visit hospital outpatient clinics in Turkey for malnutrition and sarcopenia risks. The study focuses on patients attending oncology, neurology, and geriatric clinics to better understand these conditions across diverse patient groups. This non-interventional, cross-sectional design means participants are observed without receiving experimental treatments. Participants are screened once during their outpatient visit without any study treatments or interventions. The study collects information on malnutrition risk, sarcopenia risk, body mass index, calf circumference, hand grip strength, biochemical parameters, healthcare use, and nutrition treatments. Data is gathered on the screening day only. During the study visit, researchers will assess physical and biochemical measures to evaluate nutrition and muscle health. Participants provide informed consent before any assessments. The study measures malnutrition and sarcopenia risks as primary outcomes on the first day and includes several secondary measures related to body composition and healthcare use. The study will continue enrolling participants until April 2027.
Actively Recruiting
This clinical trial studies seladelpar, a drug being evaluated for its effects on people with primary biliary cholangitis PBC who have compensated cirrhosis. The main goal is to compare seladelpar with a placebo to see how it impacts event-free survival EFS, which measures the time until certain liver-related events occur over a period of up to 156 weeks. This research is led by Gilead Sciences and takes place in a phase 3 setting, aiming to better understand treatment outcomes for PBC patients with cirrhosis. Participants with Child-Pugh class A cirrhosis will receive 10 mg of seladelpar orally once daily, while those with Child-Pugh class B will receive 5 mg once daily, both for up to 36 months. Another group with either Child-Pugh class A or B will receive a placebo matching the study drug daily for the same duration. After 156 weeks, participants with Child-Pugh class A or B who remain on the study drug may continue seladelpar at the respective doses for an additional maximum of 3 years during an open-label extension phase. Participants will be monitored throughout the study with regular assessments to evaluate liver function and clinical events related to PBC and cirrhosis. Researchers will measure outcomes such as event-free survival, overall survival, time to hospitalization, and liver transplant-free survival. Safety and liver health will be closely followed using laboratory tests and imaging. The total participation time may extend up to several years, depending on continued study drug use and follow-up requirements.